PURPOSE The COVID-19 pandemic has imposed a unique challenge to oncology patients. Outcome data on COVID-19 in patients with cancer from the Indian subcontinent are scarce in the literature. We aimed to evaluate the outcome of patients with COVID-19 on active systemic anticancer therapy. MATERIALS AND METHODS This is a retrospective study of patients with solid organ malignancies undergoing systemic therapy with a diagnosis of COVID-19 between March 2020 and February 2021. COVID-19 was diagnosed if a reverse transcriptase polymerase chain reaction assay from oropharyngeal or nasopharyngeal swab was positive for severe acute respiratory syndrome coronavirus 2. The objectives were to evaluate the outcome of COVID-19 and factors predicting the outcome. RESULTS A total of 145 patients were included with a median age of 58 years (range, 20-81 years). Treatment was curative in 60 (42%) patients. Of all symptomatic cases (n = 88, 61%), 50 had mild, 27 had moderate and 19 had severe COVID-19–related symptoms as per WHO criteria. Fifty (34%) patients required hospitalization with a median duration of hospital stay of 12 days (range, 4-25 days); five patients required intensive care unit admission. The rest were treated with home isolation and did not require further hospitalization. Twenty-two (15%) patients died, and the risk of death was significantly associated with severity of symptoms (odds ratio, 91.3; 95% CI, 9.1 to 919.5, P = .0001) but not with any other clinical factors. Drug holiday was given to 63 (44%) patients with a median duration of 25 days (range, 7-88 days). The median duration to reverse transcriptase polymerase chain reaction–negative was 16 days (range, 7-62 days). CONCLUSION COVD-19–related death rate was 15% among patients with solid organ malignancies. The severity of the symptoms was related to mortality. The majority of patients with mild symptoms were treated at home isolation.
【초록키워드】 COVID-19, coronavirus, therapy, Mortality, intensive care, Hospitalization, COVID-19 pandemic, severity, Cancer, Home isolation, Symptom, drug, outcome, Retrospective study, Nasopharyngeal swab, Patient, Mild, Oropharyngeal, Admission, moderate, patients, Odds ratio, malignancy, Hospital stay, death rate, Indian subcontinent, risk of death, acute respiratory syndrome, Factor, Mild symptom, 95% CI, median age, malignancies, symptomatic case, clinical factors, anticancer, positive, organ, transcriptase, oncology patients, FIVE, polymerase chain, evaluate, significantly, diagnosed, required, median, treated, majority, unique, COVID-19 in patient, COVID-19–related symptom, curative, diagnosis of COVID-19, patients died, patients required hospitalization, patients with COVID-19, severity of symptom, was related, WHO criteria, 【제목키워드】 COVID-19, India, experience, center, Solid, Tertiary,